Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
RETRACTED: Kim et al. Hair Cortisol and Fe-BARQ: Evaluating Chronic Stress and Behavior in Cats with Chronic Kidney Disease. <i>Animals</i> 2025, <i>15</i>, 889. [PDF]
Animals (Basel)Kim GH, Lee K, Choi HS, Han JS, Kim SA.
europepmc +1 more source
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Insights into a long life without cancer: The case of the bowhead whale
Molecular Oncology, EarlyView.Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley +1 more source
Assessment of two feed additives consisting of <i>Lactiplantibacillus plantarum</i>ATCC PTA-6139 and <i>Lacticaseibacillus paracasei</i>ATCC PTA-6135 for all animal species (Pioneer Hi-Bred International, Inc). [PDF]
EFSA JEFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) +17 more
europepmc +1 more source
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
Modernizing drug development and ensuring global equity in the organoid revolution. [PDF]
Commun BiolDzakah EE +6 more
europepmc +1 more source
Molecular cancer prevention: Intercepting disease
Molecular Oncology, EarlyView.Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source
Regulatory integration of new approach methodologies for human-relevant developmental and reproductive toxicity (DART) assessment: A systematic cross-sector review. [PDF]
Toxicol RepKumbhar S, Borude S, Deshmukh R.
europepmc +1 more source